(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid manufacturers
- AM966
-
- $33.00 / 5mg
-
2025-12-09
- CAS:1228690-19-4
- Min. Order:
- Purity: 98.06%
- Supply Ability: 10g
|
| | (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Basic information |
| Product Name: | (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid | | Synonyms: | [1,1'-BIPHENYL]-4-ACETIC ACID, 4'-[4-[[[(1R)-1-(2-CHLOROPHENYL)ETHOXY]CARBONYL]AMINO]-3-METHYL-5-ISOXAZOLYL]-;(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid;AM 966;4'-[4-[[[(1R)-1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid;{4'-[4-({[(1R)-1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]-4-biphenylyl}acetic acid;AM 966; AM-966;CS-2784;AM966,Lysophospholipid Receptor,inhibit,Inhibitor,AM-966,AM 966,LPL Receptor | | CAS: | 1228690-19-4 | | MF: | C27H23ClN2O5 | | MW: | 490.93 | | EINECS: | | | Product Categories: | | | Mol File: | 1228690-19-4.mol | ![(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Structure](CAS/GIF/1228690-19-4.gif) |
| | (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Chemical Properties |
| Boiling point | 659.4±55.0 °C(Predicted) | | density | 1.330±0.06 g/cm3 (20 ºC 760 Torr) | | storage temp. | Store at -20°C | | solubility | ≥24.55 mg/mL in DMSO; insoluble in H2O; ≥2.24 mg/mL in EtOH with gentle warming and ultrasonic | | form | solid | | pka | 4.21±0.10(Predicted) | | color | White to off-white |
| | (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Usage And Synthesis |
| Uses | AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM). | | Biological Activity | am966 is a selective, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (lpa1) with ic50 values of 17 and 19 nm for human or mouse lpa1, respectively [1]. relative to lpa2, 3, 4, 5 receptors, am966 shows 10-fold and 100-fold more selective in mouse and human cell lines for lpa1, respectively [1]. | | in vitro | am966 shows to inhibit lpa-induced chemotaxis in imr-90 human lung fibroblasts, a2058 human melanoma cells and cho cells expressing lpa1 receptors [1]. | | in vivo | am966 has been demonstrated to reduce total balf cells, ldh activity, balf collagen and total tgfβ concentrations in bleomycin-induced mice. moreover, am966 has been reported to block lung fibrosis, reduce lung inflammation and maintain body weight in mice induced by bleomycin [1]. | | target | LPA1 receptor | | references | [1] swaney js1, chapman c, correa ld, stebbins kj, bundey ra, prodanovich pc, fagan p, baccei cs, santini am, hutchinson jh, seiders tj,parr ta, prasit p, evans jf, lorrain ds. a novel, orally active lpa(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. br j pharmacol. 2010 aug;160(7):1699-713. |
| | (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Preparation Products And Raw materials |
|